Fresenius Medical Care (NYSE:FMS – Get Free Report) is expected to be announcing its earnings results before the market opens on Tuesday, February 18th. Analysts expect Fresenius Medical Care to post earnings of $0.41 per share and revenue of $5.65 billion for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.
Fresenius Medical Care Stock Down 3.3 %
Shares of NYSE FMS opened at $23.46 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. The stock has a market capitalization of $13.76 billion, a PE ratio of 19.38, a price-to-earnings-growth ratio of 0.80 and a beta of 0.93. Fresenius Medical Care has a 12-month low of $17.93 and a 12-month high of $25.25. The stock’s fifty day simple moving average is $23.46 and its two-hundred day simple moving average is $21.51.
Wall Street Analyst Weigh In
A number of equities analysts recently issued reports on the company. Truist Financial raised their target price on Fresenius Medical Care from $23.00 to $25.00 and gave the stock a “hold” rating in a research note on Monday, January 6th. Berenberg Bank initiated coverage on Fresenius Medical Care in a research note on Wednesday, November 6th. They issued a “buy” rating and a $25.60 target price for the company. StockNews.com upgraded Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. Finally, Bank of America upgraded Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research note on Monday, December 2nd.
Fresenius Medical Care Company Profile
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Further Reading
- Five stocks we like better than Fresenius Medical Care
- 5 Top Rated Dividend Stocks to Consider
- Roblox’s Big Dip: A Chance to Get in on the Vaunted Gaming Stock?
- NYSE Stocks Give Investors a Variety of Quality Options
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- How to Profit From Value Investing
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
Receive News & Ratings for Fresenius Medical Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care and related companies with MarketBeat.com's FREE daily email newsletter.
